Pemetrexed and LBH589 in Patients With Advanced Non-Small Cell Lung Cancer
Status:
Terminated
Trial end date:
2015-07-01
Target enrollment:
Participant gender:
Summary
LBH589 is a drug that may slow down the growth of cancer cells or kill cancer cells by
blocking certain enzymes. LBH589 has shown effects against cancer in laboratory studies and
in studies using animals; however, it is not known if this medicine will show the same
activity in humans. As of May 2006, approximately 100 patients have received treatment with
either an intravenous or capsule form of LBH589. Only the capsule form of LBH589 will be used
in this study. In addition, information from other research studies and laboratory studies
suggests that this study drug may help to treat lung cancer.
The main goal during the Phase I portion of this research study is to find out the highest
and safest dose of LBH589 that can be given in combination with pemetrexed in subjects with
lung cancer without causing severe side effects. The main goal of the Phase II portion of
this study is to find how the patient's lung cancer responds to the LBH589 in combination
with pemetrexed.
This study will also investigate how the patient's body processes the combination of LBH589
and pemetrexed. To determine this, the investigators will measure the amount of study drug in
the patient's blood. This will be done with a series of blood tests, called pharmacokinetic
(PK) tests. Other purposes of this study will be to determine the side effects of LBH589 in
combination with pemetrexed and whether or not this combination is effective in treating your
type of cancer.